Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Viking Thera (VKTX)

Viking Thera (VKTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 547,140
  • Shares Outstanding, K 72,758
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,780 K
  • 60-Month Beta 2.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.15
  • Number of Estimates 10
  • High Estimate -0.13
  • Low Estimate -0.20
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -87.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.45 +13.27%
on 07/29/20
7.81 -6.53%
on 07/30/20
+0.64 (+9.61%)
since 07/06/20
3-Month
6.25 +16.80%
on 05/07/20
8.36 -12.65%
on 06/23/20
+0.81 (+12.48%)
since 05/06/20
52-Week
3.26 +123.93%
on 03/17/20
8.87 -17.70%
on 12/26/19
+0.07 (+0.97%)
since 08/06/19

Most Recent Stories

More News
Viking Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

, /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today...

VKTX : 7.23 (-3.86%)
Viking Therapeutics to Participate in Upcoming Investor Conferences

, /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...

VKTX : 7.23 (-3.86%)
Viking Therapeutics to Report Financial Results for Second Quarter 2020 on July 29, 2020

, /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders,...

VKTX : 7.23 (-3.86%)
Viking Therapeutics Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting

, /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today...

VKTX : 7.23 (-3.86%)
Viking Therapeutics to Participate in Upcoming Investor Conferences

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that...

VKTX : 7.23 (-3.86%)
Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that...

VKTX : 7.23 (-3.86%)
Viking Therapeutics to Participate in 19th Annual Needham Healthcare Conference

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that...

VKTX : 7.23 (-3.86%)
Viking Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial...

VKTX : 7.23 (-3.86%)
Viking Therapeutics to Participate in Upcoming Investor Conferences

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that...

VKTX : 7.23 (-3.86%)
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2019 on February 26, 2020

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that...

VKTX : 7.23 (-3.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade VKTX with:

Business Summary

Viking Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in development of novel therapies for metabolic and endocrine disorders. Its product candidate consists of VK5211, VK0214, VK0612 and VK2809 which are in different clinical trial. Viking Therapeutics, Inc. is based in LA...

See More

Key Turning Points

2nd Resistance Point 7.66
1st Resistance Point 7.59
Last Price 7.23
1st Support Level 7.40
2nd Support Level 7.28

See More

52-Week High 8.87
Last Price 7.23
Fibonacci 61.8% 6.73
Fibonacci 50% 6.07
Fibonacci 38.2% 5.40
52-Week Low 3.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar